Ovarian Cancer Therapeutics in APAC Market Analysis to 2020

1
Ovarian Cancer Therapeutics in Asia- Pacific
Markets to 2020- Off- patent Chemo- regimens to
Retain Dominance Despite New Launches
Published on 31 January, 2015 Number of
pages 126 Single User Price 4995
Ovarian CnacerTherapeutics market in APAC is
expected not be driven by new drug approvals, but
primarily by inflation, and the increase in the
prevalence of OC. Market revenue is forecast to
rise at a limited CAGR of 5.1 to 417.6m in
2020.
2
Summary of the ReportMarketIntelReports
Research, a leading business intelligence
provider, has released its latest research
report, "Ovarian Cancer Therapeutics in
Asia-Pacific Markets to 2020 - Off-patent
Chemo-regimens to Retain Dominance Despite New
Launches". The report provides estimates of the
market size for 2013, along with forecasts until
2020 for the Asia-Pacific markets of India,
China, Australia and Japan. It also covers
disease epidemiology, treatment algorithms,
treatment patterns, in-depth analysis of clinical
trials including failure rates and pipeline
analysis, and analysis of deals relevant to
Ovarian Cancer (OC). Platinum-based
chemotherapy, predominantly the chemotherapy
regimen paclitaxel and carboplatin, is the
standard of care for the treatment of
platinum-sensitive OC (both first-line and
recurrent). The initial treatment is quite
effective, with the majority of patients entering
remission. However, almost all relapse, and after
successive periods of remission and relapse
either die or progress to platinum-resistant
disease, for which the prognosis is poor. There
is a clear gap in the market for maintenance
therapies, as well as for more effective
treatment options in platinum-resistant or
refractory patients.
Click Here To Check Complete Report
3

• Scope of the Report
• The report analyzes treatment usage patterns,
  drug types available and pipeline and market
  forecasts for OC. It covers and includes -
• A brief introduction to OC, including the
  diseases pathogenesis, risk factors and
  diagnosis
• In-depth analysis of the drug combinations used
  in the treatment of OC, including analyses of
  their safety, efficacy, and place in the disease
  treatment algorithm, as well as a heat map
  comparing the drug combinations in terms of
  safety and efficacy
• A comprehensive review of the pipeline for OC
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market in the forecast
  period the pipeline is analyzed on the basis of
  phase distribution, molecule type and molecular
  target, and route of administration
• Additional in-depth analysis of pipeline drug
  clinical trials by phase, molecule type, trial
  size, and trial duration, and program failure
  rate analyses for each molecule type and
  mechanism of action

Download Sample Brochure
4

• Reasons to Buy
• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to -
• Understand the efficacy and safety of the current
  monotherapies and drug combinations used in the
  treatment of OC, with in-depth analysis of the
  disease treatment algorithm
• Understand the key signaling pathways and
  molecular targets currently under investigation
  in OC drug development
• Understand the vast scope of the pipeline,
  including which molecule types and mechanisms of
  action are prominent
• Observe the trends in clinical trial duration and
  size among clinical phases and molecule types,
  and use the clinical trial failure rate analysis
  to assess the risk profiles of current and/or
  future developmental programs for OC therapeutics
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  in the OC therapeutics market

Make an Inquiry Before Buying
5
Ovarian Cancer Therapeutics in Asia- Pacific
Markets to 2020- Off- patent Chemo- regimens to
Retain Dominance Despite New Launches
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Ovarian Cancer Therapeutics in Asia- Pacific
Market are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Ovarian Cancer
Therapeutics in Asia- Pacific Market Report